Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
David Kirn
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Physiology
Living Beings
Disorders
Chemicals & Drugs
Procedures
Anatomy
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
9
Thorne, Stephen
9
Wang, Yaohe
8
Heise, Carla
7
Lemoine, Nicholas
6
Randlev, Britta
5
Ganly, Ian
5
Hermiston, Terry
5
Francis, Jennelle
5
Hallden, Gunnel
4
Halldén, Gunnel
4
Brooks, Gabriel
4
Liu, Ta-Chiang
4
Romel, L
4
Reid, Tony
4
Nemunaitis, John
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of David Kirn (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Nguyên Thi Lien-Anh; Abdelbary Hesham; Arguello Meztli; Breitbach Caroline; Leveille Simon; Diallo Jean-Simon; Yasmeen Amber; Bismar Tarek A; Kirn David; Falls Theresa; Snoulten Valerie E; Vanderhyden Barbara C; Werier Joel; Atkins Harold; Vähä-Koskela Markus J V; Stojdl David F; Bell John C; Hiscott John
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(39):14981-6.
-
2008: Park Byeong-Ho; Hwang Taeho; Liu Ta-Chiang; Sze Daniel Y; Kim Jae-Seok; Kwon Hyuk-Chan; Oh Sung Yong; Han Sang-Young; Yoon Jin-Han; Hong Sook-Hee; Moon Anne; Speth Kelly; Park Chohee; Ahn Young-Joo; Daneshmand Manijeh; Rhee Byung Geon; Pinedo Herbert M; Bell John C; Kirn David H
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
The lancet oncology 2008;9(6):533-42.
-
2008: Cheong S C; Wang Y; Meng J-H; Hill R; Sweeney K; Kirn D; Lemoine N R; Halldén G
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.
Cancer gene therapy 2008;15(1):40-50.
-
2007: Kirn David H; Wang Yaohe; Le Boeuf Fabrice; Bell John; Thorne Steve H
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
PLoS medicine 2007;4(12):e353.
-
2007: Thorne Steve H; Hwang Tae-Ho H; O'Gorman William E; Bartlett David L; Sei Shizuko; Kanji Femina; Brown Christopher; Werier Joel; Cho Jin-Han; Lee Dong-Ewon; Wang Yaohe; Bell John; Kirn David H
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
The Journal of clinical investigation 2007;117(11):3350-8.
-
2007: Kirn David
Armed interference: oncolytic viruses engineered to carry antitumor shRNAs.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(2):227-8.
-
2007: Au T; Thorne S; Korn W M; Sze D; Kirn D; Reid T R
Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
Cancer gene therapy 2007;14(2):139-50.
-
2006: Kim J H; Oh J Y; Park B H; Lee D E; Kim J S; Park H E; Roh M S; Je J E; Yoon J H; Thorne S H; Kirn D; Hwang T H
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(3):361-70.
-
2006: Thorne Stephen H; Tam Betty Y Y; Kirn David H; Contag Christopher H; Kuo Calvin J
Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(5):938-46.
-
2005: Thorne Stephen H; Hermiston Terry; Kirn David
Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.
Seminars in oncology 2005;32(6):537-48.
-
2005: Liu T-C; Wang Y; Hallden G; Brooks G; Francis J; Lemoine N R; Kirn D
Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Gene therapy 2005;12(17):1333-46.
-
2005: Thorne Stephen H; Hwang Tae Ho; Kirn David H
Vaccinia virus and oncolytic virotherapy of cancer.
Current opinion in molecular therapeutics 2005;7(4):359-65.
-
2005: Thorne Stephen H; Bartlett David L; Kirn David H
The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?
Current gene therapy 2005;5(4):429-43.
-
2005: Wang Yaohe; Thorne Stephen; Hannock Joseph; Francis Jennelle; Au Tina; Reid Tony; Lemoine Nick; Kirn David; Halldén Gunnel
A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):351-60.
-
2004: Thorne Steve H; Kirn David H
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.
Expert opinion on biological therapy 2004;4(8):1307-21.
-
2004: Wu Joseph T; Kirn David H; Wein Lawrence M
Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response.
Bulletin of mathematical biology 2004;66(4):605-25.
-
2004: Wang Yaohe; Faux Steven P; Hallden Gunnel; Kirn David H; Houghton Cathy E; Lemoine Nicholas R; Patrick Graham
Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.
International journal of oncology 2004;25(1):173-8.
-
2004: Liu Ta-Chiang; Hallden Gunnel; Wang Yaohe; Brooks Gabriel; Francis Jennelle; Lemoine Nick; Kirn David
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(6):786-803.
-
2004: Hermiston Terry; Kirn David
AACR-NCL-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(2):144-6.
-
2004: Halldén Gunnel; Thorne Stephen H; Yang Jingping; Kirn David H
Replication-selective oncolytic adenoviruses.
Methods in molecular medicine 2004;90():71-90.
-
2003: Wang Yaohe; Hallden Gunnel; Hill Richard; Anand Arthi; Liu Ta-Chiang; Francis Jennelle; Brooks Gabriel; Lemoine Nick; Kirn David
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
Nature biotechnology 2003;21(11):1328-35.
-
2003: Halldén Gunnel; Hill Richard; Wang Yaohe; Anand Arthi; Liu T-Chiang; Lemoine Nick R; Francis Jennelle; Hawkins Lynda; Kirn David
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;8(3):412-24.
-
2003: Wein Lawrence M; Wu Joseph T; Kirn David H
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.
Cancer research 2003;63(6):1317-24.
-
2003: Hecht J Randolph; Bedford Rudolph; Abbruzzese James L; Lahoti Sandeep; Reid Tony R; Soetikno Roy M; Kirn David H; Freeman Scott M
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):555-61.
-
2002: Reid Tony; Galanis Eva; Abbruzzese James; Sze Dan; Wein Lawrence M; Andrews James; Randlev Britta; Heise Carla; Uprichard Margaret; Hatfield Michael; Rome Larry; Rubin Joseph; Kirn David
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Cancer research 2002;62(21):6070-9.
-
2002: Kirn David; Niculescu-Duvaz Ion; Hallden Gunnel; Springer Caroline J
The emerging fields of suicide gene therapy and virotherapy.
Trends in molecular medicine 2002;8(4 Suppl):S68-73.
-
2001: Reid T; Galanis E; Abbruzzese J; Sze D; Andrews J; Romel L; Hatfield M; Rubin J; Kirn D
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Gene therapy 2001;8(21):1618-26.
-
2001: Wu J T; Byrne H M; Kirn D H; Wein L M
Modeling and analysis of a virus that replicates selectively in tumor cells.
Bulletin of mathematical biology 2001;63(4):731-68.
-
2001: Kirn D; Martuza R L; Zwiebel J
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.
Nature medicine 2001;7(7):781-7.
-
2001: Kirn D
Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.
Expert opinion on biological therapy 2001;1(3):525-38.
-
2001: Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Gene therapy 2001;8(10):746-59.
-
2001: Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Gene therapy 2001;8(4):308-15.
-
2001: Kirn D
Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
Gene therapy 2001;8(2):89-98.
-
2001: Nemunaitis J; Khuri F; Ganly I; Arseneau J; Posner M; Vokes E; Kuhn J; McCarty T; Landers S; Blackburn A; Romel L; Randlev B; Kaye S; Kirn D
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):289-98.
-
2000: Heise C; Lemmon M; Kirn D
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4908-14.
-
2000: Heise C; Ganly I; Kim Y T; Sampson-Johannes A; Brown R; Kirn D
Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Gene therapy 2000;7(22):1925-9.
-
2000: Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Cancer research 2000;60(22):6359-66.
-
2000: Heise C; Hermiston T; Johnson L; Brooks G; Sampson-Johannes A; Williams A; Hawkins L; Kirn D
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.
Nature medicine 2000;6(10):1134-9.
-
2000: Khuri F R; Nemunaitis J; Ganly I; Arseneau J; Tannock I F; Romel L; Gore M; Ironside J; MacDougall R H; Heise C; Randlev B; Gillenwater A M; Bruso P; Kaye S B; Hong W K; Kirn D H
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Nature medicine 2000;6(8):879-85.
-
2000: Heise C; Kirn D H
Replication-selective adenoviruses as oncolytic agents.
The Journal of clinical investigation 2000;105(7):847-51.
-
2000: Ganly I; Kirn D; Eckhardt G; Rodriguez G I; Soutar D S; Otto R; Robertson A G; Park O; Gulley M L; Heise C; Von Hoff D D; Kaye S B;
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):798-806.
-
2000: Rogulski K R; Freytag S O; Zhang K; Gilbert J D; Paielli D L; Kim J H; Heise C C; Kirn D H
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
Cancer research 2000;60(5):1193-6.
-
1999: Heise C C; Williams A; Olesch J; Kirn D H
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.
Cancer gene therapy 1999;6(6):499-504.
-
1999: Kirn D; Hermiston T
Induction of an oncogenic fusion protein by a viral gene--a new chapter in an old story.
Nature medicine 1999;5(9):991-2.
-
1999: Heise C C; Williams A M; Xue S; Propst M; Kirn D H
Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.
Cancer research 1999;59(11):2623-8.
-
1998: Kirn D; Hermiston T; McCormick F
ONYX-015: clinical data are encouraging.
Nature medicine 1998;4(12):1341-2.
-
1997: Heise C; Sampson-Johannes A; Williams A; McCormick F; Von Hoff D D; Kirn D H
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
Nature medicine 1997;3(6):639-45.
-
1996: Bischoff J R; Kirn D H; Williams A; Heise C; Horn S; Muna M; Ng L; Nye J A; Sampson-Johannes A; Fattaey A; McCormick F
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
Science (New York, N.Y.) 1996;274(5286):373-6.
-
1995: Qiu R G; Chen J; Kirn D; McCormick F; Symons M
An essential role for Rac in Ras transformation.
Nature 1995;374(6521):457-9.
Sign-in to see more
